Glycan modifications to the gp120 immunogens used in the RV144 vaccine trial improve binding to broadly neutralizing antibodies.

To date, the RV144 HIV vaccine trial has been the only study to show that immunization can confer protection from HIV infection. While encouraging, the modest 31.2% (P = 0.04) efficacy achieved in this study left significant room for improvement, and created an incentive to optimize the AIDSVAX B/E...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Rachel C Doran, Gwen P Tatsuno, Sara M O'Rourke, Bin Yu, David L Alexander, Kathryn A Mesa, Phillip W Berman
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Public Library of Science (PLoS) 2018-01-01
Цуврал:	PLoS ONE
Онлайн хандалт:	http://europepmc.org/articles/PMC5916523?pdf=render
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!